List of Publications by Year
in descending order

53 papers	**13,190** citations	117453 **34** h-index	168136 **53** g-index
53 all docs	**53** docs citations	**53** times ranked	**17417** citing authors

#	Article	IF	Citations
1	Untangling the ErbB signalling network. Nature Reviews Molecular Cell Biology, 2001, 2, 127-137.	16.1	5,977
2	The ERBB network: at last, cancer therapy meets systems biology. Nature Reviews Cancer, 2012, 12, 553-563.	12.8	766
3	Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers. Cell, 2020, 182, 1044-1061.e18.	13.5	691
4	Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nature Reviews Molecular Cell Biology, 2011, 12, 104-117.	16.1	597
5	A module of negative feedback regulators defines growth factor signaling. Nature Genetics, 2007, 39, 503-512.	9.4	506
6	Circular RNAs are long-lived and display only minimal early alterations in response to a growth factor. Nucleic Acids Research, 2016, 44, 1370-1383.	6.5	484
7	The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 4995-5000.	3.3	396
8	Roles for Growth Factors in Cancer Progression. Physiology, 2010, 25, 85-101.	1.6	342
9	Endocytosis and Cancer. Cold Spring Harbor Perspectives in Biology, 2013, 5, a016949-a016949.	2.3	314
10	The circ<scp>RNA</scp>â€"micro<scp>RNA</scp> code: emerging implications for cancer diagnosis and treatment. Molecular Oncology, 2019, 13, 669-680.	2.1	300
11	Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. Biochemistry, 1990, 29, 11024-11028.	1.2	228
12	Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: Implications for cancer immunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 1915-1920.	3.3	225
13	CircRNAs: role in human diseases and potential use as biomarkers. Cell Death and Disease, 2021, 12, 468.	2.7	191
14	Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 3294-3299.	3.3	161
15	EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance. Cancers, 2021, 13, 2748.	1.7	148
16	Epiregulin Is a Potent Pan-ErbB Ligand That Preferentially Activates Heterodimeric Receptor Complexes. Journal of Biological Chemistry, 1998, 273, 10496-10505.	1.6	141
17	Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 13252-13257.	3.3	135
18	Coupled preâ€"mRNA and mRNA dynamics unveil operational strategies underlying transcriptional responses to stimuli. Molecular Systems Biology, 2011, 7, 529.	3.2	126

#	ARTICLE	IF	CITATIONS
19	Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network. EMBO Journal, 1998, 17, 5948-5963.	3.5	109
20	EGF Decreases the Abundance of MicroRNAs That Restrain Oncogenic Transcription Factors. Science Signaling, 2010, 3, ra43.	1.6	100
21	Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 1815-1820.	3.3	98
22	Two Phases of Mitogenic Signaling Unveil Roles for p53 and EGR1 in Elimination of Inconsistent Growth Signals. Molecular Cell, 2011, 42, 524-535.	4.5	93
23	EGR1 and the ERKâ€ERF axis drive mammary cell migration in response to EGF. FASEB Journal, 2012, 26, 1582-1592.	0.2	88
24	Epigen, the Last Ligand of ErbB Receptors, Reveals Intricate Relationships between Affinity and Mitogenicity. Journal of Biological Chemistry, 2005, 280, 8503-8512.	1.6	83
25	Altered p53 functionality in cancer-associated fibroblasts contributes to their cancer-supporting features. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 6410-6415.	3.3	81
26	<i>TP53</i> missense mutations in PDAC are associated with enhanced fibrosis and an immunosuppressive microenvironment. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	57
27	Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of antiâ€cancer antibodies: IUPHAR Review 18. British Journal of Pharmacology, 2016, 173, 1407-1424.	2.7	56
28	Synaptojanin 2 is a druggable mediator of metastasis and the gene is overexpressed and amplified in breast cancer. Science Signaling, 2015, 8, ra7.	1.6	53
29	Cancer therapeutic antibodies come of age: Targeting minimal residual disease. Molecular Oncology, 2007, 1, 42-54.	2.1	48
30	An oligoclonal antibody durably overcomes resistance of lung cancer to thirdâ€generation <scp>EGFR</scp> inhibitors. EMBO Molecular Medicine, 2018, 10, 294-308.	3.3	46
31	Examination of HER3 targeting in cancer using monoclonal antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 839-844.	3.3	45
32	A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways. Clinical Cancer Research, 2018, 24, 5610-5621.	3.2	43
33	SILAC identifies LAD1 as a filamin-binding regulator of actin dynamics in response to EGF and a marker of aggressive breast tumors. Science Signaling, 2018, 11, .	1.6	41
34	Inhibition of pancreatic carcinoma by homo- and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 15389-15394.	3.3	40
35	Navigatorâ€3, a modulator of cell migration, may act as a suppressor of breast cancer progression. EMBO Molecular Medicine, 2015, 7, 299-314.	3.3	34
36	Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor. Cancers, 2020, 12, 2394.	1.7	34

#	Article	IF	Citations
37	Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer. Science Signaling, 2015, 8, ra53.	1.6	33
38	An antibody to amphiregulin, an abundant growth factor in patients' fluids, inhibits ovarian tumors. Oncogene, 2016, 35, 438-447.	2.6	33
39	Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment. Advances in Cancer Research, 2020, 147, 1-57.	1.9	32
40	Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors. Seminars in Cell and Developmental Biology, 2016, 50, 164-176.	2.3	31
41	Structure and function of epigen, the last EGFR ligand. Seminars in Cell and Developmental Biology, 2014, 28, 57-61.	2.3	30
42	A recombinant decoy comprising EGFR and ErbB-4 inhibits tumor growth and metastasis. Oncogene, 2012, 31, 3505-3515.	2.6	28
43	Cancer Immunotherapy: The Dawn of Antibody Cocktails. Methods in Molecular Biology, 2019, 1904, 11-51.	0.4	25
44	Tailored cancer immunotherapy using combinations of chemotherapy and a mixture of antibodies against EGF-receptor ligands. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 12559-12563.	3.3	22
45	ETS Proteins Bind with Glucocorticoid Receptors: Relevance for Treatment of Ewing Sarcoma. Cell Reports, 2019, 29, 104-117.e4.	2.9	16
46	Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models. EMBO Molecular Medicine, 2021, 13, e13144.	3.3	13
47	Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans. Cell Death and Disease, 2022, 13, 274.	2.7	11
48	EGF receptor family: twisting targets for improved cancer therapies. Growth Factors, 2014, 32, 74-81.	0.5	10
49	Targeting autocrine amphiregulin robustly and reproducibly inhibits ovarian cancer in a syngeneic model: roles for wildtype p53. Oncogene, 2021, 40, 3665-3679.	2.6	8
50	Steering tumor progression through the transcriptional response to growth factors and stroma. FEBS Letters, 2014, 588, 2407-2414.	1.3	7
51	TSHZ2 is an EGF-regulated tumor suppressor that binds to the cytokinesis regulator PRC1 and inhibits metastasis. Science Signaling, 2021, 14, .	1.6	7
52	Inhibition of a pancreatic cancer model by cooperative pairs of clinically approved and experimental antibodies. Biochemical and Biophysical Research Communications, 2019, 513, 219-225.	1.0	4
53	Host-Dependent Phenotypic Resistance to EGFR Tyrosine Kinase Inhibitors. Cancer Research, 2021, 81, 3862-3875.	0.4	3